<div class="raw-html-embed"><a href="https://libratech.ai/ch/?utm_source=partner&amp;utm_medium=website&amp;utm_campaign=wkch_libra_prsp_staempfli_07_2026
">Stämpfli - L’innovation technologique au service de la littérature juridique - Testez gratuitement !</a></div>

Über uns

À propos de nous

Nachhaltigkeit

Durabilité

Open Access

Karriere

Carrière

Aboverträge Kündigen

Résiliation d’abonnement

Vertrag widerrufen

Résiliation de contrat 

Datenschutz

Protection des données

Impressum

Mentions légales

Zahlung und Lieferung

Paiement et livraison

Libra

Was ist Libra?

C'est quoi Libra ?

Kostenlos testen

Tester gratuitement

LEXIA

LEXIA Arbeitsrecht

Was ist LEXIA?

C'est quoi LEXIA ?

LEXIA Familienrecht

Zeitschriften

Revues

recht

Pflegerecht

ZBJV

forumpoenale

ZStrR

Anwaltsrevue

Revue de l'avocat

RSAS

FamPra.ch

ASYL

Life Science Recht

BlAR

Sachbuch

Livres spécialisés

LOKI

Semaphor

Fokusthemen

Focus

Thema

Recht studieren

Arbeitsrecht

Droit du travail

Studium

Études

Familienrecht

Droit de la famille

Sozialversicherungsrecht

Droit des assurances sociales

Strafrecht

Droit pénal

Aktienrecht

Droit des sociétés anonymes

Publikationen

Publications

Literatur

Digitales Angebot

Bücher

Livres

Buchreihen

Collections

Onlinemodule LEXIA

Modules en ligne LEXIA

recht.ch

Studienliteratur

Littérature pour les études

Dienstleistungen

Services

Dienstleistungen für

Corporate Books

Publishing Lösungen

Aktuelles

Geschäftskunden

Professionnels

Corporate Publishing

Content solutions

Buchhandlungen

Librairies

Veranstaltungen

Événements

Presse

Dozierende

Enseignants

Studierende

Étudiants

Inserierende

Annonceurs

Newsletter

Blog

Autorinnen/Autoren

Auteurs

Unsere Schreibenden

Hilfe

Unsere Autorinnen und Autoren

Liste

Autorenlounge

Espace des auteurs

Bei uns publizieren

Publier chez nous

Autorenstimmen

Témoignages

Verlag

Éditions

Themen

Mehr wissen

Mitarbeitende

Collaborateurs

Geschichte

Histoire

Vision und Mission

Vision et mission

Unser Magazin

Notre magazine

Unternehmenskultur

Culture d'entreprise

Partner

Partenaires

Kontakt

Contact

Shop

Schweizer Recht

Ausländisches Recht

Über unseren Shop

Neuerscheinungen

Nouveautés

Unsere Funktionen

Nos fonctions

Vorankündigungen

À paraître

Nach Rechtsgebiet

Par domaine juridique

Kommentare

Commentaires

Gesamtkatalog

Catalogue complet

ENSAYO

Sam Quinones

Noelia González Barrancos

Tierra de sueños

La verdadera historia de la epidemia de opiáceos en Estados Unidos

Routledge Studies in Public Economics and Finance

This book deals with the emergence of intellectual monopolies. It explores different ways of producing knowledge, thus showing alternatives to the current dominant paradigm which is based on turning knowledge produced collectively into intangible assets, owned by a few leading corporations.

A New Policy Agenda for Health, Energy, and Data Governance

The Privatisation of Knowledge

Alejandro Javier Otero

Manual de prevención de adicciones

Dile no

The inside story of the race to develop Ozempic - the world's first truly effective and safe obesity drug - and its potentially revolutionary effects on public health, and our deeper culture and values.'A FASCINATING DEEP DIVE' Guardian'VERY ENGAGING' New Scientist'ENLIGHTENING' Publishers WeeklyA 'cure' for obesity has long evaded the pharmaceutical industry, until the development of Ozempic: a diabetes medication that targets the GLP-1 hormone and makes people feel fuller for longer.After decades of research, Ozempic's creator Novo Nordisk quickly became one of the most valuable companies in Europe. Now it struggles to keep up with its rivals in an explosive and lucrative market for weight-loss injections. The treatment is so effective that it's already disrupted industries from healthcare to fast food to fashion. Financial investment has skyrocketed and public demand continues to soar alongside celebrity endorsements. Beyond million-dollar profits, countless lives could now be saved from preventable diseases, but one question remains: are these drugs too good to be true?Through original reporting and rigorous research, Aimee Donnellan uncovers the complicated history of a medical breakthrough that is changing the world, while raising difficult questions about inequality, morality, our beauty ideals and the pursuit of thinness. Along the way, Donnellan profiles the female scientist whose contributions to the discovery of GLP-1 were overlooked and some of the earliest Ozempic users share powerful testimonies.The Hunger Game is a revelatory, gripping and urgent study of the unexpected consequences of finally getting what we've wanted for so long.'A lively tale of the stunning rise of Ozempic. This detailed, eye-opening account is bolstered by an insider look at commercial drug development' Irish Times'The definitive account of a singular global force - essential reading to help us understand what has been unleashed and what may be coming next' Andy Slavitt, author of Preventable'[A] Meticulously reported account ... and it is done very well - briskly and brightly ... Donnellan has performed a public service by taking down the first draft of history: by speaking to the main players and untangling the rivalries and disputes' The Times'A riveting read ... Donnellan captures the drama behind the science ... and explores the wider implications for society, health and business in this deeply researched book' John Collingridge, Guardian business editor-Previously published as Off the Scales.

The Inside Story of Ozempic and the Race to Cure Obesity

Off the Scales

A Sunday Times Book of the Year 'A welcome antidote to the dangerous cult of overdiagnosis and the commodification of normal distress' PHILIPPA PERRY How can we reconsider the way in which we think about, treat and care for those in distress? More and more people are being diagnosed with ADHD and autism. More and more people are being diagnosed with mental disorders. Young people are being medicalised for behaviours that might be explained as entirely normal in other parts of the world. Distress has been commodified over many decades by pharmaceutical companies, the media and the psychiatric establishment. So how can we know when distress is normal and when it is something that needs to be treated? In Searching for Normal, Sami Timimi explores the political and cultural context of these phenomena and presents a deeply humane approach that looks at the person as a whole - their family context, their culture, their personal resilience - and advocates for a reframing of how we think about and treat distress.

A New Approach to Understanding Mental Health, Distress and Neurodiversity

Searching for Normal

Una universidad del noroeste de Estados Unidos tiene, más o menos, las mismas salas de una universidad chilena, consultan las mismas bases de datos y, si bien es cierto que sus fondos totales son mayores, sería difícil que alguien se atreviera a apostar a que bastaría con aumentar los fondos para que se eliminara cualquier diferencia de productividad científica o calidad de la enseñanza. Que nadie lo tome a mal si creemos que, bajo cierto nivel, las carencias de recursos son una dificultad extraordinariamente difícil de remontar. Sin embargo, también es posible creer que eso no basta. Y no basta en la universidad como no basta en las empresas grandes o chicas o el Estado. No basta.

Juan Andrés Pucheu

Lo que cambia son las personas: casos de gestión del cambio en empresas, Estado y ONGs

Le Big Pharma est un sujet qui très souvent en littérature s'oriente sur un mode polémique. Dominique Winand a commis un ouvrage unique qui décrypte les arcanes de cette industrie souvent controversée parce que finalement mal connue. Mais au-delà de la présentation détaillée et de l'explication, l'auteur livre le sujet à sa propre analyse, à la lumière de son vécu d'expert ayant effectué toute sa carrière au sein de grands laboratoires pharmaceutiques. Ainsi, par cette approche expérientielle, l'auteur nous dévoile à la fois la réalité objective et sa propre vision de cette industrie, ainsi que les liens de celle-ci avec son environnement, dont les autorités de santé et les hôpitaux. Il nous explique l'organisation de l'information médicale et détaille les différentes fonctions présentes dans cette industrie. Enfin, il aborde les épineux sujets de la vaccination et de la crise du Covid, toujours en s'appuyant sur son expérience et son expertise dans ce domaine.
Cet ouvrage très complet de présentation et d'analyse s'adresse aux futurs professionnels de l'industrie pharmaceutique ainsi qu'aux professionnels de santé, comme à des lecteurs simplement curieux des modalités de fonctionnement de ce secteur si spécifique et en attente de véracité, face aux avalanches des fausses informations dont ils sont abreuvés via les médias en ligne et les réseaux sociaux.

Big Pharma mode d'emploi

Wir befinden uns im Übergang vom industriellen zum kybernetischen Zeitalter. Die Wirtschaftshistorikerin Andrea Komlosy wirft dazu einen Blick zurück, um die Corona-Krise als dynamisierendes Element der Zeitenwende verständlich zu machen. Komlosy ordnet Zyklen der Konjunktur und der globalen Hegemonie sowie Epochen der Menschheitsgeschichte historischen Einschnitten zu - vom Jagen und Sammeln über die Agrarrevolution und die Industriegesellschaft bis zum aktuellen Umbruch, der ins kybernetische Zeitalter führt. Dieser Übergang korrespondiert mit einem neuen Wachstumszyklus der Ökonomie, die durch Digitalisierung, Robotik und Schnitt stellen zwischen Mensch und Maschine geprägt ist. Pharma, Biotech und Nanotechnologie stellen die Leitbranchen des Übergangs dar. Gleichzeitig erleben wir die Erosion der westlichen Vorherrschaft und verstärkte geopolitische Rivalität um die hegemoniale
Nachfolge.
Künstliche Intelligenz, Industrie 4.0, New Green Deal, Great Reset und die Messung aller Körperregungen und Gedanken beruhen auf Big Data. Mit den Corona-Gesetzen wurden Home Offi ce und Online-Handel zur Grundlage des Überlebens. Sie dienten der Verhaltenseinübung in neue Kulturtechniken. Medizinische Überwachung, Bewegungskontrolle und biopolitische Konditionierung verwandeln den Körper in ein Interventionsfeld für Datenextraktion, Optimierung und Kontrolle.
Covid-19 wird an Schrecken verlieren. Die Akzeptanz von Verdatung und Tracking ist jedoch Bestandteil des Alltags geworden. Schließungen und Absonderungen können jederzeit reaktiviert werden, wenn dieser Trend keine antisystemische Gegenbewegung zu entfachen vermag. Eine solche muss Lebensqualität statt Komplexität zum Ziel erheben sowie Selbstbestimmung und demokratische Kontrolle der zukünftigen Entwicklung einfordern.

Corona, Big Data und die kybernetische Zukunft

Zeitenwende

Leyes comentadas

Este libro es fruto de las tesis presentadas por el autor tanto en la Especialización en Derecho Penal de la Universidad Austral, en la Maestría en Drogadependencia de la Universidad Nacional de Córdoba como en el Doctorado en Derecho de la Pontifica Universidad Católica Argentina, en las que ha condensado lo pertinente a cada una de ellas en los comentarios del articulado de la Ley de Estupefacientes Nº 23.737. Representa una herramienta jurídica con la que se puede acceder de manera rápida y clara a las partes medulares de la jurisprudencia relevante y la interpretación doctrinal sobre los distintos aspectos de la mencionada ley.

Eduardo Santiago Caeiro

María Victoria Escalera

Comentada y anotada con reseñas jurisprudenciales

Ley de Estupefacientes Nº 23.737

For Blood and Money tells the little-known story of how an upstart biotechnology company created a one-in-a-million cancer drug, and how the core team-denied their share of the profits-went and did it again. In this epic saga of money and science, veteran financial journalist Nathan Vardi explains how the invention of two of the biggest cancer drugs in history became (for their backers) two of the greatest Wall Street bets of all time.
In the multibillion-dollar business of biotech, where pharmaceutical companies, the government, hedge funds, and venture capitalists have spent billions on funding, experimentation, and treatments, a single molecule can stop cancer in its tracks-and make the people who find that rare molecule astonishingly rich. For Blood and Money follows a small team at a biotech start-up in California, who have found one of these rare molecules. Their compound, known as a BTK inhibitor, seems to work on a vicious type of leukemia. When patients start rising from their hospice beds, the team knows they're onto something big.
What follows is a story of genius, pathos, and drama, in which vivid characters navigate a world of corporate intrigue and ambiguous morality. Vardi's narrative immerses readers in the recent explosion of biotech start-ups. He describes the scientists, doctors, and investors who are risking everything to develop new, life-saving treatments, and introduces suffering patients for whom the stakes are life-or-death. A gripping nonfiction read, For Blood and Money illustrates why it's so hard to bring new drugs to market, explains why they are so expensive, and examines how profit-driven venture capitalists are shaping the future of medicine.

Billionaires, Biotech, and the Quest for a Blockbuster Drug

For Blood and Money

For fans of Phoebe Waller-Bridge and Miranda July comes a whip-smart, irresistible novel about a college senior who has 48 hours to sell her recently deceased mother's surprise stash of rare pills, or suffer the consequences. &nbsp; Arvy Keening is just trying to get through the week. Tantalizingly close to leaving her college years at Westheimer University behind, all she has to do is pass her finals, pack up her life, and ship off to San Francisco for a prestigious Big Pharma internship. The problem? Arvy just found 200 hits of Molly in her dead mother’s closet. And when two drug dealers come to collect what they are owed, they reveal that the pills are not Molly, but Mona—a rare pharmaceutical that induces intense orgasms. The dealers give Arvy an ultimatum: Sell 200 Monas in 48 hours or die. &nbsp;&nbsp; To aid in her seemingly impossible quest, Arvy recruits Wolf, Westheimer's resident drug dealer who also happens to be infuriatingly charming and distractingly sexy. In a race against the clock, Arvy and Wolf barrel through their college town, leaving a series of erotic shenanigans in their wake; appealing to horny co-eds, lonely barflies, and a mysterious sorority whose sisters have their own ideas for Mona’s potential uses. But if Mona has a knack for unleashing visceral reactions in the body, what will it unlock in Arvy, who has been repressing grief over her mother’s death for weeks? &nbsp;&nbsp; Unashamedly brash, bold, and blistering, 200 Monas is a truly one-of-a-kind read, a playful and honest examination of sexuality and grief, and a sharp, searing love letter on how to release all that’s inside you. &nbsp;

A Novel

200 Monas

The pharmaceutical industry is broken. From the American hedge fund manager who hiked the price of an AIDS pill overnight to the children's cancer drugs left intentionally to expire in a Spanish warehouse, the signs of this dysfunction are all around. A system built to drive innovation and patient care has been distorted to boost profits. Unless we take action we risk a dramatic decline in the pace of drug development and a future in which medicines go to the highest bidder. In Sick Money investigative journalist Billy Kenber offers a diagnosis of an industry in crisis and a prescription for how we can fight back.

Sky-high Prices and Dirty Tricks: Inside the Global Pharmaceutical Industry

Sick Money

This book deals with the emergence of intellectual monopolies. It explores different ways of producing knowledge, thus showing alternatives to the current dominant paradigm which is based on turning knowledge produced collectively into intangible assets, owned by a few leading corporations. It discusses a paradox: knowledge creation by government-sponsored research infrastructures (RI) or by non-profit institutions, including universities, is increasingly appearing in the form of "open science" - ideas and data are widely available in the public domain. However, such knowledge is privatised downstream by new oligopolies. These oligopolies, such as the Tech Giants, are protected by legislation on intellectual property rights that restricts further access to knowledge. This process contributes to increasing social inequality. 

The book suggests alternative policy options to counteract this process: the design of new players with a public mission and a coalition of governments as patient investors for the long-term benefit not just of the citizens of one jurisdiction but for creating global public goods. Proposals are presented for launching European R&amp;D infrastructures related to three major long-term challenges: health risks, climate change and Big Data governance. These knowledge-intensive enterprises should offer innovation as a public good, for example in new biomedical fields underinvested by private firms, disruptive 'green' technologies, digital platforms based on transparent users' ownership of data. 

Offering a balanced combination of theories and practical applications including interesting case studies, the book will appeal to students, scholars and researchers of public economics and governance. It will also find an audience among policymakers, practitioners and government officials.

Tierra de sueños

Autres titres sur ce thème